Verona Pharma to Report First Quarter 2025 Financial Results and Provide Corporate Update
Verona Pharma (Nasdaq: VRNA) has scheduled its first quarter 2025 financial results announcement for Tuesday, April 29, 2025. The company will host an investment community conference call at 9:00 a.m. EDT / 2:00 p.m. BST to discuss the financial results and provide a corporate update.
Investors can participate via phone by dialing +1-800-715-9871 (US callers) or +1-646-307-1963 (international callers). A live webcast will be available through the Events and Presentations section on the company's investor webpage, with audio replay accessible for 90 days.
Verona Pharma (Nasdaq: VRNA) ha programmato l'annuncio dei risultati finanziari del primo trimestre 2025 per martedì 29 aprile 2025. La società terrà una conference call per la comunità degli investitori alle 9:00 EDT / 14:00 BST per discutere i risultati finanziari e fornire un aggiornamento aziendale.
Gli investitori potranno partecipare telefonicamente chiamando il numero +1-800-715-9871 (per gli Stati Uniti) o +1-646-307-1963 (per chiamate internazionali). Una diretta web sarà disponibile nella sezione Eventi e Presentazioni della pagina investitori dell'azienda, con la possibilità di ascoltare la registrazione audio per 90 giorni.
Verona Pharma (Nasdaq: VRNA) ha programado el anuncio de sus resultados financieros del primer trimestre de 2025 para el martes 29 de abril de 2025. La compañía realizará una llamada de conferencia para la comunidad inversora a las 9:00 a.m. EDT / 2:00 p.m. BST para analizar los resultados financieros y ofrecer una actualización corporativa.
Los inversores podrán participar por teléfono marcando +1-800-715-9871 (llamadas desde EE. UU.) o +1-646-307-1963 (llamadas internacionales). Habrá una transmisión en vivo disponible en la sección de Eventos y Presentaciones en la página de inversores de la empresa, con la posibilidad de acceder a la grabación de audio durante 90 días.
Verona Pharma (나스닥: VRNA)는 2025년 4월 29일 화요일에 2025년 1분기 재무 결과 발표를 예정하고 있습니다. 회사는 동부 표준시 오전 9시 / 영국 서머타임 오후 2시에 투자자 대상 컨퍼런스 콜을 개최하여 재무 결과를 논의하고 기업 업데이트를 제공합니다.
투자자들은 미국 내 전화 +1-800-715-9871 또는 국제 전화 +1-646-307-1963으로 참여할 수 있습니다. 회사 투자자 웹페이지의 이벤트 및 프레젠테이션 섹션에서 생중계 웹캐스트가 제공되며, 오디오 재생은 90일간 이용 가능합니다.
Verona Pharma (Nasdaq : VRNA) a programmé l'annonce de ses résultats financiers du premier trimestre 2025 pour le mardi 29 avril 2025. La société organisera une conférence téléphonique destinée à la communauté des investisseurs à 9h00 EDT / 14h00 BST pour discuter des résultats financiers et fournir une mise à jour d'entreprise.
Les investisseurs peuvent participer par téléphone en composant le +1-800-715-9871 (appels depuis les États-Unis) ou le +1-646-307-1963 (appels internationaux). Un webcast en direct sera disponible dans la section Événements et Présentations sur la page investisseurs de la société, avec un accès à la rediffusion audio pendant 90 jours.
Verona Pharma (Nasdaq: VRNA) hat die Bekanntgabe der Finanzergebnisse für das erste Quartal 2025 für Dienstag, den 29. April 2025, geplant. Das Unternehmen wird eine Telefonkonferenz für die Investoren-Community um 9:00 Uhr EDT / 14:00 Uhr BST abhalten, um die Finanzergebnisse zu besprechen und ein Unternehmensupdate zu geben.
Investoren können telefonisch teilnehmen, indem sie +1-800-715-9871 (für Anrufer aus den USA) oder +1-646-307-1963 (für internationale Anrufer) wählen. Ein Live-Webcast ist im Bereich Veranstaltungen und Präsentationen auf der Investorenseite des Unternehmens verfügbar, mit einer Audio-Wiedergabe, die 90 Tage lang zugänglich ist.
- None.
- None.
LONDON and RALEIGH, N.C., April 15, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for the first quarter ended March 31, 2025 on Tuesday, April 29, 2025 and host an investment community conference call at 9:00 a.m. EDT / 2:00 p.m. BST to discuss these financial results and provide a corporate update.
To participate, please dial one of the following numbers and ask to join the Verona Pharma call:
- +1-800-715-9871 for callers in the United States
- +1-646-307-1963 for international callers
A live webcast will be available on the Events and Presentations link on the Investors page of the Company’s website, www.veronapharma.com, and the audio replay will be available for 90 days.
For further information please contact:
| Verona Pharma plc | Tel: +1-844-341-9901 |
| Victoria Stewart, Senior Director of Investor Relations and Communications | IR@veronapharma.com |
| Argot Partners US Investor Enquiries | Tel: +1-212-600-1902 verona@argotpartners.com |
| Ten Bridge Communications International / US Media Enquiries | Tel: +1-781-316-4424 tbcverona@tenbridgecommunications.com |
| Wendy Ryan | |
About Verona Pharma
Verona Pharma is a biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of chronic respiratory diseases with significant unmet medical needs. OhtuvayreTM (ensifentrine) is the Company’s first commercial product and the first inhaled therapy for the maintenance treatment of COPD that combines bronchodilator and non-steroidal anti-inflammatory activities in one molecule. Ensifentrine has potential applications in non-cystic fibrosis bronchiectasis, cystic fibrosis, asthma and other respiratory diseases. For more information, please visit www.veronapharma.com.
FAQ
When will Verona Pharma (VRNA) release Q1 2025 earnings?
How can investors join Verona Pharma's Q1 2025 earnings call?
What time is VRNA's Q1 2025 earnings call?
How long will VRNA's Q1 2025 earnings call recording be available?
